HARVARD BIOSCIENCE INC
For the period ended Dec 31, 2025. Filed Mar 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 13, 2026
HBIO$9.09+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| HARVARD BIOSCIENCE, INC. | |||
|---|---|---|---|
| CONSOLIDATED BALANCE SHEETS | |||
| (In thousands, except share and per share data) | |||
| December 31, | |||
| 2025 · 2024 | |||
| Assets | |||
| Current assets: | |||
| Cash and cash equivalents | $8,614 | $4,108 | |
| Accounts receivable, net | 16,043 | 14,866 | |
| Inventories | 20,805 | 23,245 | |
| Other current assets | 2,763 | 2,898 | |
| Total current assets | 48,225 | 45,117 | |
| Property, plant and equipment, net | 4,787 | 5,106 | |
| Operating lease right-of-use assets | 7,172 | 6,132 | |
| Goodwill | 9,559 | 56,324 | |
| Intangible assets, net | 7,639 | 11,132 | |
| Other long-term assets | 2,689 | 2,833 | |
| Total assets | $80,071 | $126,644 | |
| Liabilities and Stockholders' Equity | |||
| Current liabilities: | |||
| Current portion of long-term debt | $ | - | $36,956 |
| Accounts payable | 3,652 | 4,787 | |
| Contract liabilities | 3,447 | 3,806 | |
| Other current liabilities | 14,861 | 9,409 | |
| Total current liabilities | 21,960 | 54,958 | |
| Long-term debt, net | 35,870 | - | |
| Deferred tax liability | 317 | 710 | |
| Operating lease liabilities | 6,882 | 6,381 | |
| Other long-term liabilities | 1,308 | 1,255 | |
| Total liabilities | 66,337 | 63,304 | |
| Stockholders' equity: | |||
| Preferred stock, par value $0.01 per share, 5,000,000 shares authorized | - | - | |
| Common stock, par value $0.01 per share, 80,000,000 shares authorized: 44,719,894 shares issued and outstanding at December 31, 2025; 44,074,475 shares issued and outstanding at December 31, 2024 | 447 | 441 | |
| Additional paid-in-capital | 239,669 | 236,579 | |
| Accumulated deficit | (214,710) | (158,010) | |
| Accumulated other comprehensive loss | (11,672) | (15,670) | |
| Total stockholders' equity | 13,734 | 63,340 | |
| Total liabilities and stockholders' equity | $80,071 | $126,644 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.